Option chain shows key data for McEwen Mining Inc Warrants (22/11/2024)'s stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for McEwen Mining Inc Warrants (22/11/2024).

McEwen Mining Inc Warrants (22/11/2024) (OTC:MQMNW) Stock, Option Chain

McEwen Mining Inc Warrants (22/11/2024)

Mawson Infrastructure Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIGI#NASDAQ">MIGI</a>) ("Mawson" or "the Company"), a publicly-traded technology company focused on digital infrastructure platforms for artificial intelligence (AI), high-performance computing (HPC), and digital assets markets, today announced its unaudited business and operational update for December 2024.
<ul>
<li>Digital Colocation Monthly Business Revenue was up 69% Y/Y, to about $4.49 million growing from $2.66 million in December 2023, and up 8% M/M growing from $4.18 million in November 2024.</li>
<li>Total Monthly Revenue up 7% M/M to about $5.26 million from $4.9 million in November 2024.</li>
<li>Monthly Energy Management Business Revenue was up 25% M/M from $0.33 million in November 2024 to $0.41 million in December 2024 and Digital Assets Mining Monthly Business Revenue was $0.36 million.</li>
<li>Total Current Operating Hash Rate (EH) is about 4.98 EH/s (exahashes per second)</li>
<li>Mawson recently signed a new digital colocation customer agreement with a NASDAQ-listed publicly traded company as a customer on January 3, 2025
<ul>
<li>Digital colocation services for 5,880 miners or approximately 20 MW at Mawson's facilities, initial digital colocation customer agreement term is for 12 months, and the parties can extend upon mutual agreement.</li>
<li>Further strengthens Mawson's position as a leading industry provider of digital infrastructure and colocation services in the attractive PJM market, which is North America's largest competitive and deregulated wholesale power market.</li>
<li>Upon completion of this deployment, Mawson expects to operate and manage approximately 41,500 miners.</li>
<li>Combined Total Current Operating Hash Rate (EH) expected to increase to about 5.10 EH/s (includes colocation and self-mining across our facilities).1</li>
</ul>
</li>
<li>Company also has an additional site in Ohio under development which is expected to add an initial 24 MW to the Company's currently operating 129 MW across its sites, growing the Company's total operating capacity to 153 MW, upon completion with further potential expansion of its hashrate.</li>
<li>Mawson supports innovative, agile, efficient, and scalable approaches to AI infrastructure and compute, and invites AI/HPC ecosystem companies to discuss opportunities to collaborate on artificial intelligence, high-performance and accelerated computing solutions.</li>
</ul>

News

MAWSON INFRSTRUCTURE GRP by Mawson Infrastructure Group Inc.

MIGI

Mawson Infrastructure Reports 69% Growth in Colocation Revenue, Secures New Colocation Deal, Projects Hash Rate Increase with Expanded Ohio Facility

CICC analyst Zijie Yang initiates coverage on Roblox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBLX#NYSE">RBLX</a>) with a Outperform rating.

Initiation

Analyst Ratings

RBLX

CICC Initiates Coverage On Roblox with Outperform Rating

QUIK

QuickLogic Expands Into Turkiye And UAE With Magenta Distribution Agreement

Adaptive Biotechnologies Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, and NeoGenomics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEO#NASDAQ">NEO</a>), a leading oncology testing services company, today announced a multi-year exclusive strategic commercial collaboration that will advance minimal residual disease (MRD) monitoring options for patients with select blood cancers.

ADPT

Adaptive Biotechnologies and NeoGenomics Partner to Enhance MRD Monitoring for Blood Cancer Patients

Announces expansion of metrology suite to support the estimated $400 million critical films market with launch of Iris&#x2122; G2 metrology system

ONTO

Onto Innovation Secures $69M Deal With Leading DRAM Manufacturer And Launches Iris™ G2 Metrology System

Emergent BioSolutions Says It Gained Exclusive Commercial Rights To KLOXXADO (naloxone HCI) Nasal Spray From Hikma Pharmaceuticals

Verastem Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTM#NASDAQ">VSTM</a>), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced it has exercised early the option to license from GenFleet Therapeutics VS-7375 (also known as GFH375), a potential best-in-class oral and selective KRAS G12D (ON/OFF) inhibitor. In addition, the Company announced preliminary clinical data from the Phase 1 study being conducted by GenFleet in China.

VSTM

Verastem Licenses KRAS G12D Inhibitor VS-7375 Early, Reports Phase 1 Data from GenFleet Study

ZenaTech, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZENA#NASDAQ">ZENA</a>) (FSE: 49Q) ("ZenaTech"), a technology company specializing in AI (Artificial Intelligence) drones, Drone as a Service, enterprise SaaS and Quantum Computing solutions announces that its subsidiary company ZenaDrone has begun work on an all gas-powered version of the ZenaDrone 1000 drone to enable longer range flight times specifically for US Defense and NATO market use. The company plans to submit a proposal to test this model with the US Air Force through the SBIR (Small Business Innovation Research) Long-Duration Aircraft Program.

Government

Regulations

ZENA

ZenaTech Develops Gas-Powered ZenaDrone 1000 for US Defense and NATO Markets, Plans Proposal to Test Long-Range Drone with US Air Force Under SBIR Program

Deutsche Bank analyst Omotayo Okusanya initiates coverage on Rexford Industrial Realty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/REXR#NYSE">REXR</a>) with a Hold rating and announces Price Target of $40.

Price Target

REXR

Deutsche Bank Initiates Coverage On Rexford Industrial Realty with Hold Rating, Announces Price Target of $40

Deutsche Bank analyst Omotayo Okusanya initiates coverage on First Industrial Realty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FR#NYSE">FR</a>) with a Hold rating and announces Price Target of $52.

Deutsche Bank Initiates Coverage On First Industrial Realty with Hold Rating, Announces Price Target of $52

Deutsche Bank analyst Omotayo Okusanya initiates coverage on Terreno Realty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRNO#NYSE">TRNO</a>) with a Hold rating and announces Price Target of $60.

TRNO

Deutsche Bank Initiates Coverage On Terreno Realty with Hold Rating, Announces Price Target of $60

Stereotaxis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STXS#NYSE">STXS</a>), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that physicians at Oulu University Hospital in Finland have successfully treated the first patients using the advanced Genesis Robotic Magnetic Navigation (RMN) System from Stereotaxis.

STXS

Stereotaxis' Genesis Robotic System Debuts in Finland, Treats First Patients

Deutsche Bank analyst Omotayo Okusanya initiates coverage on EastGroup Props (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EGP#NYSE">EGP</a>) with a Buy rating and announces Price Target of $180.

Deutsche Bank Initiates Coverage On EastGroup Props with Buy Rating, Announces Price Target of $180

D. Boral Capital analyst Jason Kolbert maintains Artelo Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARTL#NASDAQ">ARTL</a>) with a Buy and maintains $6 price target.

ARTL

D. Boral Capital Maintains Buy on Artelo Biosciences, Maintains $6 Price Target

Cyngn Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYN#NASDAQ">CYN</a>) today announced that it has secured $33 million in funding. This funding positions the company to accelerate its growth and deliver on its mission to proliferate industrial autonomous vehicles.

Cyngn Secures $33M Funding to Advance Industrial Autonomous Vehicle Technology

D. Boral Capital analyst Jason Kolbert maintains Anixa Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANIX#NASDAQ">ANIX</a>) with a Buy and maintains $10 price target.

ANIX

D. Boral Capital Maintains Buy on Anixa Biosciences, Maintains $10 Price Target

Smartkem (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMTK#NASDAQ">SMTK</a>), which is seeking to change the world of electronics using its disruptive organic thin-film transistors (OTFTs), recapped its key accomplishments for 2024 and set its goals 2025.
 Smartkem Chairman and Chief Executive Officer, Ian Jenks commented, "2024 was a pivotal year for Smartkem. In December, we raised $7.65 million and, together with our collaboration partner, were awarded a $1.1 million grant for a project to develop the world's first rollable, transparent microLED display. We uplisted to Nasdaq, increasing trading liquidity and broadening access to investors. We made significant strides in our plans to commercialize our proprietary semiconductor materials with strategic partnerships and collaborations with industry-leaders. We believe we have strengthened our position as a key player in the market for microLED displays, as well as packaging solutions for advanced computing and AI chips and CMOS for smart sensors. Looking toward 2025, we are focused on achieving qualifications and design wins with existing and new collaborations. We believe our technology will help drive adoption of advanced display and other technologies, with the microLED industry projected to grow from $150 million in 2024 to over $4 billion by 2031.

SMTK

Smartkem Recaps 2024 Milestones, Eyes 2025 Growth in Rollable MicroLED Displays and AI Chip Solutions

Full year 2024 revenue is now expected in the range of $710 to $720 million. Full year 2024 GAAP diluted earnings per share is expected in the range of $1.07 to $1.26, while Non-GAAP diluted earnings per share is expected in the range of $1.69 to $1.76.

VECO

Veeco Updates Q4 Guidance: Projects Revenues Of $175M-$185M Vs. $182.98M Estimate (Prior View: $165M-$185M); Company Sees Adjusted EPS $0.36-$0.44 Vs. $0.46 Estimate (Prior View: $0.35-$0.45)

<ul>
<li>This collaboration is part of SolarEdge's domestic manufacturing plans that have already created ~1,750 new jobs in Tampa, Florida, and Austin, Texas</li>
</ul>

SEDG

SolarEdge And Summit Ridge Energy Partner To Advance U.S. Solar Adoption With Domestically Manufactured Technology

SIG: -21% &#x7C; <a href="https://www.benzinga.com//node/42969440">Signet Jewelers shares are trading lower after the company reported a drop in total same store sales for the holiday season and lowered its Q4 guidance.</a>
&nbsp;
APLD: 38% &#x7C; <a href="https://www.benzinga.com//node/42970143">Applied Digital Secures $5B Financing Facility With Macquarie Asset Management to Expand Ellendale HPC Campus and Repay Debt</a>
&nbsp;
RGNX: 29% &#x7C; <a href="https://www.benzinga.com//node/42967838">REGENXBIO Partners with Nippon Shinyaku in $810M Deal for Hunter and Hurler Syndrome Therapies</a>

Comments

McEwen Mining Inc Warrants (22/11/2024)

McEwen Mining Inc Warrants (22/11/2024) (MQMNW) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga